1. Immune-Mediated Mechanisms in Cofactor-Dependent Food Allergy and Anaphylaxis: Effect of Cofactors in Basophils and Mast Cells
   Rosa Muñoz-Cano et al, 2021, Frontiers in Immunology CrossRef
2. Integrins as a drug target in liver fibrosis
   Syedia R. Rahman et al, 2022, Liver International CrossRef
3. ATP Secretion and Metabolism in Regulating Pancreatic Beta Cell Functions and Hepatic Glycolipid Metabolism
   Jing Li et al, 2022, Frontiers in Physiology CrossRef
4. Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic Treatment of Non-Alcoholic Fatty Liver Disease
   Takefumi Kimura et al, 2021, Frontiers in Endocrinology CrossRef
5. 2-Substituted (N)-Methanocarba A3 Adenosine Receptor Agonists: In Silico, In Vitro, and In Vivo Characterization
   Dilip K. Tosh et al, 2024, ACS Pharmacology & Translational Science CrossRef
6. Purinergic Signaling in Liver Pathophysiology
   Shanu Jain et al, 2021, Frontiers in Endocrinology CrossRef
7. Characterization of Dual-Acting A3 Adenosine Receptor Positive Allosteric Modulators That Preferentially Enhance Adenosine-Induced Gαi3 and GαoA Isoprotein Activation
   Courtney L. Fisher et al, 2022, ACS Pharmacology & Translational Science CrossRef
8. Exercise in mice ameliorates high-fat diet-induced nonalcoholic fatty liver disease by lowering HMGCS2
   Xiaoli Qian et al, 2021, Aging CrossRef
9. Direct Comparison of (N)-Methanocarba and Ribose-Containing 2-Arylalkynyladenosine Derivatives as A3 Receptor Agonists
   Dilip K. Tosh et al, 2020, ACS Medicinal Chemistry Letters CrossRef
10. Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotective effects
    Pnina Fishman et al, 2023, Purinergic Signalling CrossRef
11. Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
    Michail Kokkorakis et al, 2024, Pharmacological Reviews CrossRef
12. An Efficient Model of Non-alcoholic Fatty Liver Disease (NAFLD) Versus Current Experimental Models: Effects of Fructose, Fat, and Carbon Tetrachloride on NAFLD
    Zahra Eslami et al, 2021, Hepatitis Monthly CrossRef
13. The different effects of four adenosine receptors in liver fibrosis
    Lan Yang et al, 2024, Frontiers in Pharmacology CrossRef
14. Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease
    Yajie Fu et al, 2022, Frontiers in Pharmacology CrossRef
15. Research Progress on the Effect of Autophagy and Exosomes on Liver Fibrosis
    Yikuan Du et al, 2024, Current Stem Cell Research & Therapy CrossRef
16. Design and in vivo activity of A3 adenosine receptor agonist prodrugs
    R. Rama Suresh et al, 2020, Purinergic Signalling CrossRef
17. Selective A3 Adenosine Receptor Antagonist Radioligand for Human and Rodent Species
    R. Rama Suresh et al, 2022, ACS Medicinal Chemistry Letters CrossRef